nach oben

Virchows Archiv

Erschienen in:

01.05.2004 | Original Article

Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett’s oesophagus

verfasst von: Christine Lagorce-Pagès, François Paraf, Dominique Wendum, Antoine Martin, Jean-François Fléjou

Erschienen in: Virchows Archiv | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims

To establish the prevalence of inflammatory secretory phospholipase A2 (sPLA2) and cytoplasmic phospholipase A2 (cPLA2) expression in a surgical series of Barrett’s adenocarcinoma and associated preneoplastic lesions and to correlate this expression with clinicopathological data and prognosis.

Methods

sPLA2 and cPLA2 were analysed by means of immunohistochemistry in surgical specimens of 67 and 73 cases of Barrett’s adenocarcinomas, respectively. Barrett’s mucosa was analysed in 31 cases.

Results

Expression of sPLA2 was detected in 48% of Barrett’s mucosa negative for intraepithelial neoplasia and 63% of Barrett’s adenocarcinoma. Semi-quantitative analysis revealed a significant increase in sPLA2 expression between Barrett’s mucosa negative for intraepithelial neoplasia and adenocarcinoma. cPLA2 expression was detected in 18% of Barrett’s adenocarcinoma. An inverse correlation was found between cPLA2 expression and depth of tumour infiltration, neoplastic vascular invasion and neoplastic perineural invasion. Survival analysis showed no significant prognostic value for sPLA2 and cPLA2.

Conclusion

sPLA2 is frequently expressed in Barrett’s oesophagus. The increasing expression of sPLA2 that we observed from Barrett’s mucosa to adenocarcinoma suggests that sPLA2 could be involved in Barrett’s carcinogenesis. In contrast, cPLA2 expression is less frequently observed in Barrett’s oesophagus and is inversely associated with aggressive pathological features of the tumours.

Balsinde J, Balboa MA, Dennis EA (1998) Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA 95:7951–7956CrossRefPubMed

Balsinde J, Balboa MA, Insel PA, Dennis EA (1999) Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 39:175–189

Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289PubMed

Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 122:1101–1112PubMed

Cameron AJ (2002) Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus 15:106–108CrossRefPubMed

Clark JD, Schievella AR, Nalefski EA, Lin LL (1995) Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 12:83–117CrossRefPubMed

Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES (1997) Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 17:88–91PubMed

Dobbie Z, Muller H, Scott RJ (1996) Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis. Hum Genet 98:386–390CrossRefPubMed

Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS, Lambeau G, Giardina C, Rosenberg DW (2003) Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24:307–315CrossRefPubMed

10.

Faller G, Borchard F, Ell C, Seitz G, Stolte M, Walch A, Ruschoff J, Working Group for Gastroenterological Pathology of the German Society for Pathology (2003) Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Arch 443:597–601CrossRefPubMed

11.

Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH (2001) Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 7:3857–3861PubMed

12.

Haapamaki MM, Gronroos JM, Nurmi H, Alanen K, Kallajoki M, Nevalainen TJ (1997) Gene expression of group II phospholipase A2 in intestine in ulcerative colitis. Gut 40:95–101PubMed

13.

Haapamaki MM, Gronroos JM, Nurmi H, Alanen K, Nevalainen TJ (1999) Gene expression of group II phospholipase A2 in intestine in Crohn’s disease. Am J Gastroenterol 94:713–720PubMed

14.

Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG (1989) Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96:1249–1256PubMed

15.

Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA (1997) Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 272:14501–14504CrossRefPubMed

16.

Hong KH, Bonventre JC, O’Leary E, Bonventre JV, Lander ES (2001) Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 98:3935–3939CrossRefPubMed

17.

Jenkins GJ, Doak SH, Parry JM, D’Souza FR, Griffiths AP, Baxter JN (2002) Genetic pathways involved in the progression of Barrett’s metaplasia to adenocarcinoma. Br J Surg 89:824–837CrossRefPubMed

18.

Kashiwagi M, Friess H, Uhl W, Berberat P, Abou-Shady M, Martignoni M, Anghelacopoulos SE, Zimmermann A, Buchler MW (1999) Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis. Gut 45:605–612PubMed

19.

Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett’s esophagus. Gastroenterology 123:60–67CrossRefPubMed

20.

Kennedy BP, Soravia C, Moffat J, Xia L, Hiruki T, Collins S, Gallinger S, Bapat B (1998) Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 58:500–503PubMed

21.

Kiyohara H, Egami H, Shibata Y, Murata K, Ohshima S, Ogawa M (1992) Light microscopic immunohistochemical analysis of the distribution of group II phospholipase A2 in human digestive organs. J Histochem Cytochem 40:1659–1664PubMed

22.

Lagorce C, Fléjou JF, Muzeau F, Hénin D, Potet F (1995) Absence of c-Ki-ras gene mutation in malignant and premalignant Barrett’s oesophagus. J Clin Pathol 48:M198–M199

23.

Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Flejou JF (2003) Cyclooxygenase-2 is expressed frequently and early in Barrett’s oesophagus and associated adenocarcinoma. Histopathology 42:457–465PubMed

24.

Laurén P (1965) The two histological main types of gastric carcinoma diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49

25.

Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, Chan AS, Li R, Law S, Troyanskaya OG, Tu IP, Wong J, So S, Botstein D, Brown PO (2002) Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 99:16203–16208CrossRefPubMed

26.

MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM (1995) The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81:957–966PubMed

27.

Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96:990–996CrossRefPubMed

28.

Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, Kudo I (1998) The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem 273:14411–14423CrossRefPubMed

29.

Murata K, Egami H, Kiyohara H, Oshima S, Kurizaki T, Ogawa M (1993) Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa. Br J Cancer 68:103–111PubMed

30.

Niessen HW, Krijnen PA, Visser CA, Meijer CJ, Erik Hack C (2002) Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res 53:138–146CrossRefPubMed

31.

Paraf F, Flejou JF, Pignon JP, Fekete F, Potet F (1995) Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases. Am J Surg Pathol 19:183–191PubMed

32.

Rosenberg JC, Budev H, Edwards RC, Singal S, Steiger Z, Sundareson AS (1985) Analysis of adenocarcinoma in Barrett’s esophagus utilizing a staging system. Cancer 55:1353–1360PubMed

33.

Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G (2000) Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 118:487–496PubMed

34.

Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1–19

35.

Sobin LH, Wittekind Ch (1997) TNM classification of malignant tumors. Wiley-Liss, Inc, New-York

36.

Soydan AS, Gaffen JD, Weech PK, Tremblay NM, Kargman S, O’Neill G, Bennett A, Tavares IA (1997) Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. Eur J Cancer 33:1508–1512PubMed

37.

Soydan AS, Tavares IA, Weech PK, Temblay NM, Bennett A (1996) High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue. Eur J Cancer 32:1781–1787CrossRef

38.

Spechler SJ, Goyal RK (1986) Barrett’s esophagus. N Engl J Med 315:362–371PubMed

39.

Spirio LN, Kutchera W, Winstead MV, Pearson B, Kaplan C, Robertson M, Lawrence E, Burt RW, Tischfield JA, Leppert MF, Prescott SM, White R (1996) Three secretory phospholipase A(2) genes that map to human chromosome 1P35–36 are not mutated in individuals with attenuated adenomatous polyposis coli. Cancer Res 56:955–958PubMed

40.

Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, Taketo MM (2000) Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem 275:34013–34016PubMed

41.

Wendum D, Svrcek M, Rigau V, Boelle PY, Sebbagh N, Parc R, Masliah J, Trugnan G, Flejou JF (2003) COX-2, Inflammatory Secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol 16:130–136PubMed

42.

World Health Organization Classification of Tumours (2000) Pathology and genetics of tumours of the digestive system. Hamilton SR, Aaltonen LA

43.

Yamashita S, Yamashita J, Ogawa M (1994) Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166–1170PubMed

44.

Ying Z, Tojo H, Komatsubara T, Nakagawa M, Inada M, Kawata S, Matsuzawa Y, Okamoto M (1994) Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta 1226:201–205CrossRefPubMed

Titel: Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett’s oesophagus
verfasst von: Christine Lagorce-Pagès
François Paraf
Dominique Wendum
Antoine Martin
Jean-François Fléjou
Publikationsdatum: 01.05.2004
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 5/2004
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-004-1003-7

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett’s oesophagus

Abstract

Aims

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2004

Immunohistochemical analysis of pro- and active-caspase 3 in laryngeal squamous cell carcinoma

Salivary duct carcinoma with neuroendocrine features

Tumor with features of renal cell carcinoma and of transitional cell carcinoma

Diagnostic telepathology: long-term experience of a single institution

Mucinous non-neoplastic cyst of the pancreas accompanied by non-parasitic asymptomatic liver cysts

Reply to the letter by Dr. E.N. Beckman

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien